Bluejay Diagnostics Files 8-K

Ticker: BJDX · Form: 8-K · Filed: 2025-04-09T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-action

TL;DR

Bluejay Diagnostics filed an 8-K on 4/9/25 detailing material agreements and equity sales.

AI Summary

On April 7, 2025, Bluejay Diagnostics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing was made on April 9, 2025, and pertains to the company's operations and financial activities.

Why It Matters

This 8-K filing indicates significant corporate actions and potential financial transactions for Bluejay Diagnostics, Inc., requiring investor attention.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can impact stock price, but the specific details of the agreements are not yet fully disclosed in this summary.

Key Players & Entities

FAQ

What type of material definitive agreement did Bluejay Diagnostics, Inc. enter into?

The filing indicates Bluejay Diagnostics, Inc. entered into a material definitive agreement, but the specific nature of the agreement is not detailed in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on April 7, 2025.

What is the principal executive office address for Bluejay Diagnostics, Inc.?

The principal executive office address for Bluejay Diagnostics, Inc. is 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

What is the Commission File Number for Bluejay Diagnostics, Inc.?

The Commission File Number for Bluejay Diagnostics, Inc. is 001-41031.

What is the I.R.S. Employer Identification No. for Bluejay Diagnostics, Inc.?

The I.R.S. Employer Identification No. for Bluejay Diagnostics, Inc. is 47-3552922.

From the Filing

0001213900-25-030312.txt : 20250409 0001213900-25-030312.hdr.sgml : 20250409 20250409161534 ACCESSION NUMBER: 0001213900-25-030312 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250407 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bluejay Diagnostics, Inc. CENTRAL INDEX KEY: 0001704287 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 473552922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41031 FILM NUMBER: 25825377 BUSINESS ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: (978) 631-0152 MAIL ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 8-K 1 ea0237671-8k_bluejay.htm CURRENT REPORT false 0001704287 0001704287 2025-04-07 2025-04-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 7, 2025   Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter)   delaware   001-41031   47-3552922 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File No.)   (I.R.S. Employer Identification No.)   360 Massachusetts Avenue , Suite 203 Acton , MA 01720 (Address of principal executive offices and zip code)   ( 844 ) 327-7078 (Registrant’s telephone number, including area code)     (Former name or former address, if changed from last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol (s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   BJDX   The Nasdaq Capital Market           Item 1.01 Entry into a Material Definitive Agreement.   On April 7, 2025, Bluejay Diagnostics, Inc. (the “Company”), entered into inducement letter agreements (the “Inducement Letter Agreements”) with certain existing holders (the “Holders”) of the Company’s existing Class C warrants, pursuant to which such Holders agreed to purchase an aggregate of 1,085,10

View on Read The Filing